Metraipolis › archive › dc_a5edc35cdf10

Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer — Europe PMC PMID:42163922

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42163922
DOI
10.3389/fpubh.2026.1786699
License (as archived)
solo-consultazione
Archived
2026-11-02T16:45:01.565Z
SHA-256 of the archived text
93073122a15977e3f5e7b65d528968af798fe764275c069166cb67b459b3bbf5
Stable URL of this page
https://metraipolis.com/documento/dc_a5edc35cdf10

How to cite

Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer — Europe PMC PMID:42163922 — Europe PMC (en), https://europepmc.org/article/MED/42163922 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a5edc35cdf10 (Metraipolis archive dc_a5edc35cdf10, sha256 93073122a15977e3f5e7b65d528968af798fe764275c069166cb67b459b3bbf5)
BibTeX
@misc{dca5edc35cdf10,
  title = {Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer — Europe PMC PMID:42163922},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42163922},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a5edc35cdf10; sha256 93073122a15977e3f5e7b65d528968af798fe764275c069166cb67b459b3bbf5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42163922. Agents can read the archived copy with the MCP tool read_document.